alexa Atherosclerosis Treatments in NHLBI

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Atherosclerosis Treatments in NHLBI

Atherosclerosis and complications associated with this pathology, such as coronary artery disease, remains a leading cause of morbidity and mortality in the world. Dyslipidemia is one of the main risk factors leading to development of the atherosclerosis. Peripheral (non-hepatic) cells, including arterial and aortic cells, obtain cholesterol from either de novo synthesis or from uptake of plasma lipoproteins. To prevent atherosclerosis, excess cholesterol must be removed from cells. This process takes place through the reverse cholesterol transport pathway, a process whereby cells efflux excess cholesterol to HDL, which subsequently delivers cholesterol to the liver for excretion into the bile.


Vaisman BL, Freeman L, and Remaley AT (2014) Exploring Genetically Modified Animals for Development of New Atherosclerosis Treatments in NHLBI. J Mol Genet Med 8:109. doi: 10.4172/1747-0862.1000109

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger